Overview

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

To determine safety, tolerability, and preliminary efficacy of escalating doses of SD-101 alone and SD-101 plus ribavirin in subjects with chronic hepatitis C and no prior therapy.

Phase:

Phase 1

Details

Lead Sponsor:

Dynavax Technologies Corporation

Collaborators:

PPD
Synteract, Inc.

Treatments:

Ribavirin